Lavipharm S.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was EUR 19.554 million compared to EUR 18.258 million a year ago. Operating income was EUR 4.094 million compared to EUR 3.633 million a year ago. Net income was EUR 2.597 million compared to EUR 2.162 million a year ago. Basic earnings per share from continuing operations was EUR 0.0508 compared to EUR 0.0423 a year ago.